霍亂疫苗市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、產品、分銷管道、地區和競爭格局分類，2021-2031年

全球霍亂疫苗市場預計將從 2025 年的 9,732 萬美元大幅成長至 2031 年的 1.6,611 億美元，複合年成長率為 9.32%。

這些生物製藥，主要為口服製劑，可誘導人體對霍亂弧菌產生免疫力。市場需求成長的促進因素是霍亂疫情爆發頻率的增加，這主要歸因於氣候變化，例如嚴重的洪水和乾旱破壞了供水和衛生基礎設施。日益惡化的人道危機和不斷增加的居民流離失所問題，使得在高風險地區開展更大規模的免疫宣傳活動以降低霍亂發病率變得尤為必要。根據國際疫苗供應協調小組（ICGV）預測，到2025年，全球預計將分發超過4,000萬劑口服霍亂疫苗，以應對不斷激增的霍亂疫情和人道緊急情況。

市場促進因素

氣候變遷導致洪水和颶風肆虐，水源污染嚴重，霍亂在流行地區捲土重來，這是推動疫苗市場快速擴張的主要因素。世界衛生組織的報告顯示，2025年1月至8月期間，霍亂疫情惡化，造成409,222例病例和4,700多人死亡。這迅速消耗了現有疫苗庫存，亟需補充和分發。此外，疫苗製劑技術的進步和生產基礎設施的擴張正在改變疫苗供應動態。製藥公司和全球合作夥伴正致力於投資建設大規模生產設施並簡化監管核准，例如，巴拉特生物技術公司生產計畫2億劑疫苗，而EuBiologics有限公司承諾到2025年向聯合國兒童基金會供應7,200萬劑疫苗。

市場挑戰

儘管需求強勁且生產努力，市場仍面臨許多障礙。具體而言，全球產能不足以滿足緊急的公共衛生需求。這種生產瓶頸嚴重限制了市場規模，阻礙了產業充分利用需求。這導致了嚴重的庫存短缺、強制性的劑量分配策略、受影響地區反應遲緩以及地理擴張受限。光是2025年第一季就需要1,390萬劑疫苗，這種持續存在的缺口已導致庫存迅速消耗殆盡，仍然是限制市場進一步成長和儘早根除疾病努力的主要阻礙因素。

市場趨勢

同時，兩大趨勢正在影響市場：個人旅遊市場的成長和疫苗需求的擴大。這為前往流行地區的外國遊客帶來了高額的平均消費，從而形成了一個盈利的細分市場。例如，Valneva SE 的 Dukoral 疫苗銷售額在 2025 年上半年成長至 1,740 萬歐元。同時，全球生產和供應基礎變得更加多元化，生產基地在地理上分散，以減少對亞洲現有企業的依賴，並加強區域衛生安全。這包括供應鏈多元化以及資助技術轉移給當地製造商，尤其是在非洲，旨在確保本地具備端到端的生產能力。例如，南非 Biovac 公司於 2025 年 10 月啟動了其本地生產的口服霍亂疫苗的 I 期臨床試驗。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球霍亂疫苗市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依類型（含B次單元的O1型霍亂弧菌全細胞疫苗、O1型及O139型去活化口服疫苗）
  • 依產品（Vaxchora、Dukoral、Shanchol 等）
  • 分銷管道（醫院藥房、零售藥房、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美霍亂疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲霍亂疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區霍亂疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲霍亂疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美霍亂疫苗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球霍亂疫苗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Valneva SE
• Sanofi SA
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

The global cholera vaccines market is projected to expand significantly, growing from USD 97.32 Million in 2025 to USD 166.11 Million by 2031 at a 9.32% CAGR. These biological preparations, primarily oral formulations, induce immunity against the Vibrio cholerae bacterium. The market is propelled by the intensifying frequency of cholera outbreaks, largely attributed to climate change phenomena such as severe flooding and droughts that compromise water and sanitation infrastructure. The escalation of humanitarian crises and population displacement further necessitates rigorous mass vaccination campaigns to mitigate morbidity in high-risk zones, with over 40 million oral cholera vaccine doses allocated globally in 2025 to address surging outbreaks and humanitarian emergencies, according to the International Coordinating Group on Vaccine Provision.

Market Driver

The resurgence of cholera outbreaks in endemic regions, heavily influenced by climate change-induced events like severe floods and cyclones contaminating water, serves as the primary catalyst driving the market's urgent expansion. This escalation, which led to 409,222 cholera cases and over 4,700 deaths between January and August 2025 as reported by the WHO, has rapidly depleted existing stockpiles, creating an immediate need for replenishment and distribution. Additionally, advancements in vaccine formulation and the expansion of manufacturing infrastructure are reshaping supply dynamics; pharmaceutical companies and global alliances are investing in high-capacity production facilities and streamlining regulatory approvals, exemplified by Bharat Biotech's plan for 200 million doses annually and EuBiologics Co., Ltd's commitment to supply 72 million doses to UNICEF in 2025.

Market Challenge

Despite this robust demand and production efforts, the market faces a significant barrier: insufficient global production capacity relative to immediate public health requirements. This manufacturing bottleneck creates a hard ceiling on market volume, preventing the industry from capitalizing on demand, resulting in severe stockpile shortages, forced dose rationing strategies, delayed response times in endemic regions, and restricted geographical expansion. This persistent gap, where requests for 13.9 million doses in Q1 2025 alone rapidly depleted stock, remains the primary restraint hindering broader market expansion and timely disease elimination efforts.

Market Trends

In parallel, two key trends are influencing the market: the growth in the private travel market and prophylactic vaccination demand, offering a lucrative segment with higher price points from international tourists to endemic zones, as shown by Valneva SE's Dukoral vaccine sales growing to €17.4 million in H1 2025. Simultaneously, there's a diversification of the global manufacturing and supply base, shifting production geography to reduce reliance on Asian incumbents and enhance regional health security. This involves funding technology transfers to local manufacturers, particularly in Africa, to decentralize the supply chain and ensure indigenous end-to-end capabilities, such as Biovac in South Africa commencing Phase 1 clinical trials for its locally manufactured oral cholera vaccine in October 2025.

Key Market Players

• Valneva SE
• Sanofi S.A.
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• Shantha Biotechnics Limited
• Hilleman Laboratories Singapore Pte Ltd
• Astellas Pharma Inc.
• Incepta Pharmaceuticals Ltd.
• Bharat Biotech Ltd.
• Takeda Pharmaceutical Company Limited

Report Scope

In this report, the Global Cholera Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cholera Vaccines Market, By Type

• Whole cell V. Cholerae O1 Recombinant With B-Subunit
• Killed Oral O1 & O139

Cholera Vaccines Market, By Product

• Vaxchora
• Dukoral
• Shanchol
• Others

Cholera Vaccines Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Cholera Vaccines Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cholera Vaccines Market.

Available Customizations:

Global Cholera Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cholera Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Whole cell V. Cholerae O1 Recombinant With B-Subunit, Killed Oral O1 & O139)
  • 5.2.2. By Product (Vaxchora, Dukoral, Shanchol, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cholera Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cholera Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Cholera Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Cholera Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Distribution Channel

7. Europe Cholera Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cholera Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Cholera Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Cholera Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Cholera Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Cholera Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Cholera Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cholera Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Cholera Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Cholera Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Cholera Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Cholera Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Cholera Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cholera Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Cholera Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Cholera Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Distribution Channel

10. South America Cholera Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cholera Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Cholera Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Cholera Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cholera Vaccines Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Valneva SE
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi S.A.
• 15.3. Emergent BioSolutions Inc.
• 15.4. EuBiologics Co., Ltd.
• 15.5. Shantha Biotechnics Limited
• 15.6. Hilleman Laboratories Singapore Pte Ltd
• 15.7. Astellas Pharma Inc.
• 15.8. Incepta Pharmaceuticals Ltd.
• 15.9. Bharat Biotech Ltd.
• 15.10. Takeda Pharmaceutical Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer